We first chose to assess effects of in-vivo treatment with the pan-HDACi SAHA in NUP98-HOXD13 (NHD13) transgenic mice, which display severe symptoms resembling human MDS and die of cytopenias or transformed leukemia in 8-12 months [17]. The gene discussed is HOXD13; the disease is leukemia.